Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

CRISPR therapies offer precise gene-editing solutions for treating genetic disorders and other complex diseases. Rising prevalence of genetic conditions drives adoption, and emerging CRISPR-based ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Scientists developed a new nanostructure that triples CRISPR’s ability to enter cells, unlocking even more power to treat ...

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing ...

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is an advanced technology developed in 2012 that can be used to edit genes. It can be used to find specific DNA sequences inside ...

There was a lot of hype and excitement around gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) last year after it obtained approval for its first product, Casgevy. But that excitement has ...

We expect investors to focus on the sales performance of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline updates when the company reports its second-quarter 2025 results.

That’s why a team from UC San Diego in La Jolla set out with Yale University researchers to develop a new system for gene ...